What Happened?
Shares of medical technology company Stryker (NYSE: SYK) jumped 4.1% in the afternoon session after analyst firm Raymond James upgraded the stock to "Outperform" from "Market Perform" and set a $418 price target.
The analyst noted that Stryker had been one of the “highest quality compounders” in medical technology for the last five years. Despite this strong performance, the stock's forward valuation multiple compressed in the previous year even as financial estimates for the company trended higher. The firm's research note stated this situation did not make sense and argued that Stryker's valuation at that time represented an attractive entry point for investors.
Is now the time to buy Stryker? Access our full analysis report here.
What Is The Market Telling Us
Stryker’s shares are not very volatile and have only had 2 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 9 months ago when the stock dropped 6% on the news that stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%, while the baseline 10% tariffs remained in place for most countries.
This added layer of uncertainty reminded investors that the global trade environment remained volatile, limiting the potential for sustained market gains. Also President Trump said he was willing to accept pain in the short term, and was aware his policies could cause a recession, but he remained more mindful of a more severe case of economic depression (higher unemployment and prolonged downturn). For investors, this suggested that the administration could prioritize long-term structural shifts over near-term economic stability, further increasing policy-driven risk in the markets.
Stryker is up 4.7% since the beginning of the year, but at $364.71 per share, it is still trading 9.6% below its 52-week high of $403.53 from July 2025. Investors who bought $1,000 worth of Stryker’s shares 5 years ago would now be looking at an investment worth $1,504.
The 1999 book Gorilla Game predicted Microsoft and Apple would dominate tech before it happened. Its thesis? Identify the platform winners early. Today, enterprise software companies embedding generative AI are becoming the new gorillas. Click here for access to our special report that reveals one profitable leader already riding this wave.
